Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the ...

We also participated in investor conferences, where we presented Beamr's achievements and future plans, such as the H.C.

GARDEN CITY, NY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the closing of its ...

The offering was facilitated by ThinkEquity and is pending approval from the TSX Venture Exchange. For further insights into TSE:KWE stock, check out TipRanks’ Stock Analysis page. Trending Articles ...

The offering is expected to close on November 14, 2024, subject to customary closing conditions. ThinkEquity is acting as ...

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the secon ...

If the closing price for the Company's shares is $0.0625 or greater for a period of 10 consecutive trading days, then the warrant holders will have 30 days to exercise their warrants; otherwise, the ...